目的探讨血清同型半胱氨酸(homocysteine,Hcy)、载脂蛋白E(apolipoprotein E,ApoE)基因多态性对血管性痴呆患者认知功能的影响。方法回顾性分析于医院接受治疗的100例血管性痴呆患者病例资料作为研究对象,使用简易智力状态检查量表(mini...目的探讨血清同型半胱氨酸(homocysteine,Hcy)、载脂蛋白E(apolipoprotein E,ApoE)基因多态性对血管性痴呆患者认知功能的影响。方法回顾性分析于医院接受治疗的100例血管性痴呆患者病例资料作为研究对象,使用简易智力状态检查量表(mini-mental state examination,MMSE)评估患者认知功能,将MMSE评分为21~26分患者纳入轻度组,将10~20分患者纳入中度组,将0~9分患者纳入重度组。参照《中国痴呆与认知障碍诊治指南》给予患者常规治疗,治疗前主要检查项目包括血浆Hcy、ApoE基因多态性,治疗3个月后记录患者临床疗效;分析ApoE基因多态性、Hcy与血管性痴呆患者认知功能障碍及临床疗效的关系。结果100例血管性痴呆患者MMSE评分为16.50(9.00,20.00)分,其中轻度24例,中度49例,重度27例;重度组ApoE基因表型为ε2/4、ε4/4患者占比高于轻度组、中度组,入院时血浆Hcy水平高于轻度组、中度组,差异有统计学意义(P<0.05);行多元Logistic回归分析结果显示,血浆Hcy、ApoE基因是导致血管性痴呆患者认知功能障碍加重的危险因素(P<0.05);100例血管性痴呆患者,治疗3个月后,显效47例,好转30例,无效23例,总有效率为77.00%;行二元Logistic回归分析显示,血浆Hcy、ApoE基因均是影响血管性痴呆患者治疗效果的危险因素(P<0.05)。结论ApoE基因多态性、Hcy与血管性痴呆患者认知功能障碍病情严重程度及临床关系密切,未来临床可通过检测患者ApoE基因多态性、Hcy水平,评估患者认知障碍严重程度及治疗无效风险,针对病情严重治疗无效风险较高者,采取针对性干预,以改善患者临床疗效。展开更多
Background: We recently evaluated four laboratory assays, vascular endothelial growth factor D (VEGF-D), E-cadherin, lymphatic vessel density (LVD) measured by podoplanin, and intra-lymphatic tumor emboli (ILTE), whic...Background: We recently evaluated four laboratory assays, vascular endothelial growth factor D (VEGF-D), E-cadherin, lymphatic vessel density (LVD) measured by podoplanin, and intra-lymphatic tumor emboli (ILTE), which showed notable differences between inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer (LABC). In this study we investigated the potential of the three most quantitatively measured markers, E-cadherin, LVD and VEGF-D, to predict survival in the IBC patients. Materials and Methods: This study involved the 100 cases identified in the Inflammatory Breast Cancer Registry (IBCR) whose tumors were previously evaluated for the four assays noted above. Living patients were recontacted and survival data were available for up to 17 years. Overall survival (OS) was analyzed through the Kaplan-Meier method stratified by E-cadherin, LVD, VEGF-D, and response to chemotherapy. The differences in OS curves were compared using the log-rank test. Results: The median OS for patients with high LVD was 6.63 years (95% CI: 4.06 to 10.14), compared to median at 10 years not reached in those with low LVD (p = 0.03). There was a trend towards a longer median OS in patients with high E-cadherin (10.14, 95% CI: 6.63 to 11.67), compared with those with low E-cadherin (6.26, 95% CI: 3.42 to undeterminable). VEGF-D levels showed no correlation with survival. Conclusion: Low LVD significantly predicts better survival. High E-cadherin expression, as with non-IBC breast cancer and several other malignancies, tends to be associated with a better prognosis.展开更多
文摘目的探讨血清同型半胱氨酸(homocysteine,Hcy)、载脂蛋白E(apolipoprotein E,ApoE)基因多态性对血管性痴呆患者认知功能的影响。方法回顾性分析于医院接受治疗的100例血管性痴呆患者病例资料作为研究对象,使用简易智力状态检查量表(mini-mental state examination,MMSE)评估患者认知功能,将MMSE评分为21~26分患者纳入轻度组,将10~20分患者纳入中度组,将0~9分患者纳入重度组。参照《中国痴呆与认知障碍诊治指南》给予患者常规治疗,治疗前主要检查项目包括血浆Hcy、ApoE基因多态性,治疗3个月后记录患者临床疗效;分析ApoE基因多态性、Hcy与血管性痴呆患者认知功能障碍及临床疗效的关系。结果100例血管性痴呆患者MMSE评分为16.50(9.00,20.00)分,其中轻度24例,中度49例,重度27例;重度组ApoE基因表型为ε2/4、ε4/4患者占比高于轻度组、中度组,入院时血浆Hcy水平高于轻度组、中度组,差异有统计学意义(P<0.05);行多元Logistic回归分析结果显示,血浆Hcy、ApoE基因是导致血管性痴呆患者认知功能障碍加重的危险因素(P<0.05);100例血管性痴呆患者,治疗3个月后,显效47例,好转30例,无效23例,总有效率为77.00%;行二元Logistic回归分析显示,血浆Hcy、ApoE基因均是影响血管性痴呆患者治疗效果的危险因素(P<0.05)。结论ApoE基因多态性、Hcy与血管性痴呆患者认知功能障碍病情严重程度及临床关系密切,未来临床可通过检测患者ApoE基因多态性、Hcy水平,评估患者认知障碍严重程度及治疗无效风险,针对病情严重治疗无效风险较高者,采取针对性干预,以改善患者临床疗效。
文摘Background: We recently evaluated four laboratory assays, vascular endothelial growth factor D (VEGF-D), E-cadherin, lymphatic vessel density (LVD) measured by podoplanin, and intra-lymphatic tumor emboli (ILTE), which showed notable differences between inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer (LABC). In this study we investigated the potential of the three most quantitatively measured markers, E-cadherin, LVD and VEGF-D, to predict survival in the IBC patients. Materials and Methods: This study involved the 100 cases identified in the Inflammatory Breast Cancer Registry (IBCR) whose tumors were previously evaluated for the four assays noted above. Living patients were recontacted and survival data were available for up to 17 years. Overall survival (OS) was analyzed through the Kaplan-Meier method stratified by E-cadherin, LVD, VEGF-D, and response to chemotherapy. The differences in OS curves were compared using the log-rank test. Results: The median OS for patients with high LVD was 6.63 years (95% CI: 4.06 to 10.14), compared to median at 10 years not reached in those with low LVD (p = 0.03). There was a trend towards a longer median OS in patients with high E-cadherin (10.14, 95% CI: 6.63 to 11.67), compared with those with low E-cadherin (6.26, 95% CI: 3.42 to undeterminable). VEGF-D levels showed no correlation with survival. Conclusion: Low LVD significantly predicts better survival. High E-cadherin expression, as with non-IBC breast cancer and several other malignancies, tends to be associated with a better prognosis.
